TESARO Inc (NASDAQ:TSRO) Sells Licensing,Commercialization Rights to Janssen


TESARO Inc (NASDAQ:TSRO) has announced that it has reached an agreement with Janssen Pharmaceutical, a subsidiary of Johnson & Johnson. As per the agreement, the two companies would collaborate on the development and commercialization of niraparib, worldwide. The drug is targeted at patients suffering from prostate cancer. The drug is also undergoing phase-3 trials for ovarian and breast cancer.

Subscribe to get the latest news